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ABSTRACT 
Objective: The proposed study is focussed at developing acyclovir microemulsions for topical drug delivery systems.  QbD was applied for better 
understanding of the process and to generate design space, using quality target product profile, critical quality attributes, and risk assessment. 
The aim of the experiment is to prepare a safe, efficacious, stable and patient compliant microemulsion dosage form of Acyclovir. Materials and 
methods: Pre-formulation studies were carried out which helped in developing a suitable dosage form. UV, FTIR and DSC studies were done for 
pre-formulation and post-formulation evaluations. QbD was applied to generate design space, using QTPP, CQA, and risk assessment. 
Microemulsions of acyclovir were developed by using 32 factorial designs. Pseudo terneary phase diagrams were constructed to screen various 
surfactants and co-surfactants for the preparation of microemulsions. Two independent variables Oil Concentration (X1) and Smix Concentration 
(X2) at three levels low, medium and high were selected and response surface plots were generated. The microemulsions were prepared by 
plotting pseudo terneary phase diagrams. Various characterizations that were carried out include % transmittance, Viscosity and % drug release. 
Statistical analyses of batches and surface response studies were done to understand the effect of various independent variables on the 
dependent variables. Results and Discussions: The λmax was confirmed at 251 nm by UV spectroscopy. The melting point was determined 
experimentally to be 2460C which confirms the drug to be Acyclovir. FTIR and DSC studies confirmed that the drug is Acyclovir.  Conclusion: The 
study indicates that microemulsions of Acyclovir by QbD approach were successfully developed.  
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Acyclovir is a potent, specific antiviral drug which is active 
against herpes simplex viruses’ types I and II and varicella 
zoster virus1. Acyclovir is available as various dosage forms 
in the market which includes capsules, creams, ointments, 
tablets and suspension. Idea of microemulsions was first 
presented by Hoar and Schulman in 1940s. It is an 
arrangement of water, oil and surfactant, which is optically 
isotropic and thermodynamically stable fluid that have low 
consistency or interfacial film comprising of surfactant/co-
surfactant2. It is vehicle for enhancing drug delivery, 
optimization of dose and bioavailability of drugs3. It is well-
established that medium chain unsaturated fats impact tight 
intersections of epithelial cells, and long chain unsaturated 
fats allow lipoprotein amalgamation and consequential 
lymphatic absorption. Lately, various investigations have 
suggested that microemulsion [o/w or w/o] can possibly 
promote bioavailability of medications by means of topical 
routes. 
Quality by design (QbD) is an efficient way to bring quality 
into both product and process. QbD can be achieved by 
constructive planning of all the previous data that is 
accessible. Although it is based on certain amount of risks, it 
gives results that reduces the risk of end product failure and 
increases the chances of regulatory acceptance4. ICH Q8, ICH 
Q9 and ICH Q10 do explain the principles of QbD in the best 
way. They provide guidelines on science and risk based 
assessment, life cycle of product and various approaches in 
its development. It is also well known fact that there can be a 
great deal of unpredictability in scale up of a product from 
research and development, although the reason for failure is 
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not generally understood. QbD is an approach to be applied 
in all stages of drug discovery, production and delivery5-6. 
MATERIALS AND METHODS 
Materials  
The drug Acyclovir was obtained as gift sample from 
Aurobindo Pharma, Hyderabad. All other chemicals that 
were used in the experiment were of the analytical grade.  
Methods 
Pre-formulation studies 
Determination of melting point of Acyclovir: 
Melting point of Acyclovir was determined by open capillary 
method.  
Determination of wavelength maxima (λmax) of Acyclovir: 
Determination of wavelength maxima (λmax) was done for 
Acyclovir. 
Preparation of calibration curve for Acyclovir: 
The calibration curve of Acyclovir was plotted by taking 0.1N 
HCl as the solvent.  
Identification of Acyclovir by FT-IR Spectroscopy: 
FTIR study was carried for Acyclovir.  
Identification of Acyclovir by DSC Study:  
The thermograph of Acyclovir was obtained by DSC.  
Screening for components of microemulsion 
Most important criterion for screening of component for 
microemulsion formulation is solubility of the drug in oils, 
surfactants and co-surfactants. Solubility of Acyclovir in 
various oils, surfactants and co-surfactants was determined 
by dissolving excess amount of drug in 2 mL of each selected 
oils, surfactants and co-surfactants in 5 mL capacity 
stoppered vials separately and mixed using vortex mixer. 
Equilibrated samples were removed and centrifuged; the 
supernatant liquid was taken and filtered through 0.45 µm 
membrane filter. Concentration of Acyclovir was determined 
in each component by double beam UV-VIS 
spectrophotometer at λmax251 nm after appropriate dilution. 
Construction of pseudo ternary phase diagram 
Pseudoternary phase diagram were constructed using water 
titration method at ambient temperature (25°C). Surfactant 
and co-surfactant were in different volume ratios and 
titrated with water by drop wise under gentle agitation. 
Proper ratio of one excipient to another in microemulsion 
formulation was analysed and pseudoternary plot is 
constructed. 
Optimization of oils, surfactants and co-surfactants: 
From pseudoternary phase diagrams showing maximum 
microemulsion region, number of microemulsion with 
different formula were selected covering entire range of 
microemulsion occurrence in phase diagram. For each phase 
diagram constructed, different formulation was selected 
from microemulsion region so that drug could be 
incorporated in oil phase on following bases.  (a) Oil 
concentration should be such that it solubilizes drug (single 
dose) completely depending on solubility of drug in oil.   (b) 
Minimum concentration of Smix used for that amount of oil 
was taken.  (c) For convenience purpose, about 1 mL was 
selected as microemulsion formulation, so that it can 
increase or decreased as per requirement in proportions. 
Beauty of this system is scale up of proportions is easy, as 
system is thermodynamically stable. 
Formulation and development of Acyclovir 
microemulsion using Design of experiments [DoE] 
approach: 
A design space can signify formulation and process 
understanding viz. attributes which are related to drug 
substance, materials, equipment and finished product 
quality. For this purpose, risk assessment was done based on 
understanding process and formulation related parameters 
on microemulsion quality. Preliminary studies and later 
Design of Experimentation (DoE) was carried out for high 
risk parameters. Based on effect of critical quality attributes 
of target product profile, we proposed design space for 
obtaining robust formulation. Characterization of 
microemulsion is done for various parameters like effect of 
globule size, viscosity, %transmittance, %drug release. 
Characterization of acyclovir loaded microemulsion 
Droplet size analysis: 
Droplet size analysis of microemulsion was measured by 
diffusion method using light-scattering particle size analyser.  
Zeta potential: 
Zeta potential is measured by instrument known as 
Zetasizer. It is used to measure charge on surface of droplet 
in microemulsion. 
pH: 
pH of formulation is measured by pH meter. 
Viscosity determination: 
Viscosity of microemulsion is measure by using Brookﬁeld-
type rotary viscometer at different shear rates. 
In-vitro drug release studies 
Drug release kinetics are studied using modified method 
glass cup with cross-sectional area of 1.5 cm2 will fill with 
0.2ml of microemulsion, covered with cellophane membrane, 
sealed with rubber band and adhesive tape, and inverted 
under surface of 30 ml of phosphate buffer pH in USP XXIII 
Type I Dissolution Test Apparatus with speed of 30 rpm. 
Aliquots are withdrawn at specified time intervals and 
immediately replaced with fresh dissolution medium to 
maintain sink condition. Drug content in withdrawn samples 
will be determined spectrophotometrically at 251 nm. 
Risk Assessment to identify CQAs affecting drug product 
quality: 
Risk assessments was done to select formulation and process 
variable which may affect product quality for CQAs by 
process characterization that defines satisfactory changes in 
material and process parameters. As a final point, this can 
result in quality assurance by process design space to 
understand and develop control strategy. Critical quality 
attributes were categorized into high, medium and low risk 
parameters based on knowledge space. Usually high-risk 
parameters are considered important for Design of 
Experiments as they are having more effect than others and 
need to be in accepting multivariate ranges.  
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Figure 1 QbD approach 
 
Table 1 Independent and dependent variables 
 Independent variables – X Dependent Variables – Y 
Oil Concentration (%)  
Smix Concentration (%)  
% Transmittance 
Viscosity  
% Drug release 
 
Effect of different independent variables ( Oil concentration 
and Smix Concentration) were checked by evaluating % 
Transmittance, viscosity and %  drug release of Acyclovir 
microemulsion formulated in preliminary trial batches. 
Based on that characterization, CQAs were selected which 
have greater effect on microemulsion formulations. 
Design of Experimentation (DoE) of Acyclovir 
microemulsion by using QbD approach: 
A design space can signify formulation and process variables 
that affects attributes which are related to drug substance, 
materials, equipments and finished product quality. For this 
purpose, risk assessment was done based on understanding 
of process and formulation related parameters on 
microemulsion quality. Preliminary studies and later Design 
of Experimentation (DoE) was carried out for high risk 
parameters. Based on effect of critical quality attributes of 
target product profile, design space for obtaining robust 
formulation was proposed.  
 
RESULTS AND DISCUSSIONS 
Pre-formulation studies 
Determination of melting point of Acyclovir: 
The melting point of Acyclovir was found to be 2460C. 
Determination of wavelength maxima (λmax) of Acyclovir: 
The wavelength maxima (λmax) of Acyclovir were found to be 
251 nm.  
 
Figure 2 Wavelengthmax (λmax) of Acyclovir 
 
Preparation of calibration curve for Acyclovir: 
 
Figure 3 Calibration curve for Acyclovir 
 
Identification of Acyclovir by FT-IR Spectroscopy: 
The recorded IR spectrum of Acyclovir is 
  
 
Figure 4: FTIR spectrum of Acyclovir 
nm.
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Table 2: FT-IR peaks of Acyclovir 
Type of Vibration Standard Wave number(cm-1) Observed Wave number(cm-1) 
C=C Stretching of Aromatic 1600-1475 1465.90 
 -   tretching of     amine 3500-3300 3417.88 
N-O Stretching of N - Oxide 1300-1200 1222.87 
C-H Stretching of Piperidines 2850-3000 2937.59 
C-N Stretching of C-NH2 860-766 761.88 
 
Identification of Acyclovir by DSC Study: 
 
Figure 5: DSC thermograph 
Construction of pseudo ternary phase diagram 
Pseudo ternary phase diagrams are constructed to identify microemulsion region and suitable composition of oil, surfactant, co-
surfactant for formulation of microemulsion. From pseudoternary diagram it was found that system containing of Captex 200 as 
oily phase, Tween 20 as surfactant and PEG 400 as co-surfactant showed good microemulsifying property at Smix ratio 4:1.it was 
observed that by increasing oil content, system show appearance of coarse emulsion. It was observed that by increasing co-
surfactant in Smix ratio system show decreasing property of spontaneous microemulsion formation. Hence from this observation 
it is clear that surfactant play key role in formation of microemulsion. 
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Figure 6: Pseudo ternary phase diagram 
32 Factorial Design for Acyclovir microemulsions 
Various batches of Acyclovir microemulsion were designed by DoE using QbD approach according to 32  factorial designs which 
are as shown in Table 3. 
Table 3:  32 Factorial Designs 
Independent variable of formulation 






Oil Concentration (%) (X1) 5% 10% 15% 
Smix Concentration (%) (X2) 50% 55% 60% 
Dependent variable 
Y1= % Transmittance 
Y2 = Viscosity 
Y3 = % Drug release 
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Compositions of Factorial Batches in Coded Form 
Various batches of Acyclovir microemulsions with Eudragit RS 100 were prepared according to 32  factorial designs which are as 
shown in Table 4.: 
Table 4: Compositions of Factorial Batches in Coded Form 
Acyclovir Microemulsion 32 = 9 batches 
Batch No Variable level in coded from 
Oil Concentration (X1) Smix Concentration (X2) 
ACME1 -1 -1 
ACME2 0 -1 
ACME3 +1 -1 
ACME 4 -1 0 
ACME 5 0 0 
ACME 6 +1 0 
ACME 7 -1 +1 
ACME 8 0 +1 
ACME 9 +1 +1 
  
Formulation Design by 32 Factorial Design 
Table 5: Formulation Design by 32 Factorial Designs 











ACME1 -1  -1 5 50 
ACME2 0 -1 10 50 
ACME3 +1 -1 15 50 
ACME4 -1 0 5 55 
ACME5 0 0 10 55 
ACME6 +1 0 15 55 
ACME7 -1 +1 5 60 
ACME8 0 +1 10 60 
ACME9 +1 +1 15 60 
 
Characterization of Acyclovir microemulsions batches ACME1-ACME9: 





% Drug release 
(Y3) 
ACME1 98.5 138 23.05 
ACME2 98.6 135 26.41 
ACME3 99.8 133 28.32 
ACME 4 98.2 144 7.51 
ACME 5 98.3 142 19.42 
ACME 6 99.5 139 22.4 
ACME 7 89.2 156 10.6 
ACME 8 95.1 152 12.54 
ACME 9 96.3 148 15.14 
 
 






% Transmittance (Y1) 
Viscosity (Y2) 
% Drug release (Y3) 
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Statistical analysis of batches ACME1-ACME9  
In factorial design, amount of Oil Concentration (X1) and 
Smix Concentration (X2) were taken as independent 
variables while % Transmittance (Y1), % Viscosity (Y2) 
and % Drug Release (Y3) were selected as dependent 
variables for both factorial designs. 
Effect on % Transmittance (Y1) - Surface Response Study  
% Transmittance (Y1) =97.36-3.58* X1+1.38*X2 
Negative value of coefficient of X1 indicates decrease in 
response of Y1 i.e. % Transmittance. Positive value of 
coefficient X2, Smix concentration indicates increase in % 
Transmittance. 
Effect on Viscosity (Y2) - Surface Response Study 
Viscosity (Y2) =144.0+8.33* X1-3.00* X2 
Positive value of coefficient of X1 indicates increase in 
response of Y2 i.e. %viscosity. Negative value of coefficient 
X2, Smix Concentration indicates decrease in viscosity.  
Effect on %Drug Release (Y3) - Surface Response Study  
Drug Release Release (Y3) =18.38-6.51*X1+2.55* X2 
Negative value of coefficient of X1 indicates decrease in 
response of Y2 i.e. % Drug release. Positive value of 
coefficient X2, Smix Concentration indicates increase in 
%Drug Release. 
CONCLUSION 
The focus of the current study was to develop topical 
microemulsion drug delivery system of acyclovir using QbD 
approach. Pre-formulation studies were carried out which 
helped in developing a suitable dosage form. UV, FTIR and 
DSC studies were done for pre-formulation and post-
formulation evaluations. QbD was applied to generate design 
space, using QTPP, CQA, and risk assessment. 
Microemulsions of acyclovir were developed by using 32 
factorial designs. Pseudo terneary phase diagrams were 
constructed to screen various surfactants and co-surfactants 
for the preparation of microemulsions. Two independent 
variables Oil Concentration (X1) and Smix Concentration (X2) 
at three levels low, medium and high were selected and 
response surface plots were generated. The microemulsions 
were prepared by plotting pseudo terneary phase diagrams. 
Various characterizations that were carried out include % 
transmittance, Viscosity and % drug release. Statistical 
analyses of batches and surface response studies were done 
to understand the effect of various independent variables on 
the dependent variables.  Lastly it was concluded that 
microemulsions of Acyclovir using QbD approach were 
successfully developed. 
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